Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation

Respiratory Research

Volumn 18, Issue 1, 2017, Pages

  Lendermon, Elizabeth A ^a   Coon, Tiffany A ^a   Bednash, Joseph S ^a,b   Weathington, Nathaniel M ^a,b   McDyer, John F ^a   Mallampalli, Rama K ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CRYOPYRIN; DACTINOMYCIN; I KAPPA B; INFLAMMASOME; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; ANTIINFECTIVE AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NLRP3 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENETIC CODE; GENETIC TRANSCRIPTION; HEK CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOMODULATION; INFLAMMATION; LUCIFERASE ASSAY; LUMINESCENCE; MONOCYTE; NLRP3 GENE; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA DEGRADATION; RNA STABILITY; THP 1 CELL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; PROTEIN STABILITY;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL LINE; HEK293 CELLS; HUMANS; INFLAMMASOMES; INFLAMMATION; MONOCYTES; NF-KAPPA B; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PROTEIN STABILITY; RNA, MESSENGER;

EID: 85021318801     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-017-0608-8     Document Type: Article

References (30)

1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR, C. C. R. Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-98.
2. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978-84.
3. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell 3rd PW, Macrolide Study Group, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749-56.
4. Carr RR, Nahata MC. Azithromycin for improving pulmonary function in cystic fibrosis. Ann Pharmacother. 2004;38:1520-4.
5. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother. 2011;66:968-78.
6. Kobayashi H, Takeda H, Sakayori S, Kawakami Y, Otsuka Y, Tamura M, Konishi K, Tanimoto S, Fukakusa M, Shimada K, et al. Study on azithromycin in treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi. 1995;69:711-22.
7. Li H, Zhou Y, Fan F, Zhang Y, Li X, Yu H, Zhao L, Yi X, He G, Fujita J, Jiang D. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases. Intern Med. 2011;50:1663-9.
8. Hui D, Yan F, Chen RH. The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases. J Thorac Dis. 2013;5:613-7.
9. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004;77:1465-7.
10. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, Lordan JL, Dark JH, Corris PA. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005;172:772-5.
11. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 2005;24:1440-3.
12. Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G, Johnson G, Ward C. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax. 2015;70:442-50.
13. Lee N, Wong CK, Chan MCW, Yeung ESL, Tam WWS, Tsang OTY, Choi KW, Chan PKS, Kwok A, Lui GCY, Leung WS, Yung IMH, Wong RYK, Cheung CSK, Hui DSC. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. Antiviral Res. 2017;144:48-56.
14. Choi EY, Jin JY, Choi JI, Choi IS, Kim SJ. Effect of azithromycin on Prevotella intermedia lipopolysaccharide-induced production of interleukin-6 in murine macrophages. Eur J Pharmacol. 2014;729:10-6.
15. Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, Goto H, Barnes PJ, Ito K. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition. J Pharmacol Exp Ther. 2013;345:76-84.
16. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006;350:977-82.
17. Yamada K, Morinaga Y, Yanagihara K, Kaku N, Harada Y, Uno N, Nakamura S, Imamura Y, Hasegawa H, Miyazaki T, Izumikawa K, Kakeya H, Mikamo H, Kohno S. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. Pulm Pharmacol Ther. 2014;28:165-70.
18. Stellari FF, Sala A, Donofrio G, Ruscitti F, Caruso P, Topini TM, Francis KP, Li X, Carnini C, Civelli M, Villetti G. Azithromycin inhibits nuclear factor-kappaB activation during lung inflammation: an in vivo imaging study. Pharmacol Res Perspect. 2014;2:e00058.
19. Bosnar M, Bosnjak B, Cuzic S, Hrvacic B, Marjanovic N, Glojnaric I, Culic O, Parnham MJ, Erakovic Haber V. Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta. J Pharmacol Exp Ther. 2009;331:104-13.
20. Bosnar M, Cuzic S, Bosnjak B, Nujic K, Ergovic G, Marjanovic N, Pasalic I, Hrvacic B, Polancec D, Glojnaric I, Erakovic Haber V. Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia. Int Immunopharmacol. 2011;11:424-34.
21. Geudens N, Timmermans L, Vanhooren H, Vanaudenaerde BM, Vos R, Van De Wauwer C, Verleden GM, Verbeken E, Lerut T, Van Raemdonck DE. Azithromycin reduces airway inflammation in a murine model of lung ischaemia reperfusion injury. Transpl Int. 2008;21:688-95.
22. Gualdoni GA, Lingscheid T, Schmetterer KG, Hennig A, Steinberger P, Zlabinger GJ. Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation. Sci Rep. 2015;5:12016.
23. Bednash JS, Weathington N, Londino J, Rojas M, Gulick DL, Fort R, Han S, McKelvey AC, Chen BB, Mallampalli RK. Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity. Nat Commun. 2017;8:15203.
24. Han S, Lear TB, Jerome JA, Rajbhandari S, Snavely CA, Gulick DL, Gibson KF, Zou C, Chen BB, Mallampalli RK. Lipopolysaccharide Primes the NALP3 Inflammasome by Inhibiting Its Ubiquitination and Degradation Mediated by the SCFFBXL2 E3 Ligase. J Biol Chem. 2015;290:18124-33.
25. Wu X, Brewer G. The regulation of mRNA stability in mammalian cells: 2.0. Gene. 2012;500:10-21.
26. Lu JY, Sadri N, Schneider RJ. Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev. 2006;20:3174-84.
27. Biswas R, Datta S, Gupta JD, Novotny M, Tebo J, Hamilton TA. Regulation of chemokine mRNA stability by lipopolysaccharide and IL-10. J Immunol. 2003;170:6202-8.
28. Graham JR, Hendershott MC, Terragni J, Cooper GM. mRNA degradation plays a significant role in the program of gene expression regulated by phosphatidylinositol 3-kinase signaling. Mol Cell Biol. 2010;30:5295-305.
29. Wei Y, Bechhofer DH. Tetracycline induces stabilization of mRNA in Bacillus subtilis. J Bacteriol. 2002;184:889-94.
30. Drusano GL. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy. 2005;25:150S-8S.